Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | Recurso digital |
| Langue: | anglais |
| Publié: |
Zenodo
2025
|
| Sujets: | |
| Accès en ligne: | https://doi.org/10.5281/zenodo.18009414 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Table des matières:
- <p><span lang="EN-US">Therapeutic resistance in IDH-wildtype glioblastoma (GBM) is driven by profound cellular plasticity and a structured immunosuppressive tumor microenvironment (TME). Here, we present the Glioblastoma Resistance Insights from Treatment Atlas (GRIT-Atlas), the most comprehensive single-cell resource to date, encompassing nearly one million cells from 299 samples across primary and recurrent cohorts, including those treated with immune checkpoint blockade (ICB) and anti-angiogenic combination therapy. We identify a convergent evolutionary trajectory where therapeutic pressure selects for a specific malignant state, cNMF7 (MES-like), characterized by a synergy of hypoxia, stemness, and inflammatory signaling. Integrating spatial transcriptomics across 48 patient sections, we define a "Spatial Resistance Triad"—a core functional unit composed of cNMF7 cells, differentiation-arrested E-MDSCs, and Type VI Collagen-secreting myCAFs. This triad specifically colonizes the hypoxic microvascular proliferation (MVP) and pseudopalisading necrosis (PAN) niches. Mechanistically, we show that myCAFs act as stromal architects, constructing a fibrotic scaffold through a Collagen/Fibronectin-CD44 signaling axis. This spatial infrastructure not only physically excludes cytotoxic T cells but also provides essential cues to sustain malignant plasticity and myeloid-mediated immunosuppression. Our findings across seven independent cohorts and pan-cancer validation underscore the clinical significance of this axis in driving immunotherapy failure. Collectively, the GRIT-Atlas provides a blueprint for dismantling the "immunosuppressive sanctuaries" of GBM to overcome therapeutic resistance.</span></p>